Consumer Alert! Clomid Birth Defects
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. With all the Internet chatter on the association with birth defects and SSRIs such as Lexapro, Zoloft, Effexor, Prozac, Celexa, Paxil and anti-seizure medications such as Depakote and Topamax, one drug has been seemingly passing under the radar – Clomid. This is unfortunate
Read MoreYaz and Yasmin Safety Dangers
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. Yesterday the Food and Drug Administration finally took action concerning the dangers of the birth control pills Yaz and Yasmin. However, it is too little too late for the thousands of women who have suffered clotting events such as stroke, heart
Read MoreMichael Brady Lynch Appointed to 360 Advocacy's Advisory Board
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. As many of my readers are aware, I am very active on the speaking circuit helping to teach other attorneys on the how-tos of pharmaceutical and medical device litigation. One of the very best seminar groups is the 360 Advocacy Institute.
Read MoreFDA Warning! Black Licorice Associated with Heart Problems
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. I wish this was a Mischief Night prank because I love black licorice. But it appears that folks really should take care when consuming black licorice. The FDA warned today in advance of Halloween that consumption of large quantities of black
Read MoreMichael Brady Lynch to Speak at 360 Advocacy Institute Seminar
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. Today I received a very nice invitation to serve on the faculty at the 360 Advocacy Institute’s seminar “Medical School for Plaintiff’s Lawyers” to be held in Vegas on October 23-25 at the Encore. This will be my second seminar trip
Read MoreLive in Vegas! Mass Torts Made Perfect
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. Last night, I arrived in Las Vegas to attend the seminar Mass Torts Made Perfect. The seminar is a gathering of attorneys to discuss pharmaceutical and medical device litigation. I have probably lectured at close to a dozen Mass Torts Made
Read MoreInjury Spotlight: Bladder Cancer and Actos
Studies have shown that those who use Actos for over one year have as much as a 40 percent increase in the risk for bladder cancer. The risk seems to be increased in the male population and further increased with Actos use over two years. The Michael Brady Lynch Firm has been at the forefront of litigation involving the association between bladder cancer and Actos and is aggressively pursuing claims against the manufacturer of Actos. If you or someone you know has taken Actos and have bladder cancer, please contact me directly for a free, no-obligation evaluation of your claim.
Read MoreYaz and Clotting Dangers
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. In the years since its FDA approval, Yaz has been under attack for a troubling association with pulmonary embolism, stroke or heart attack. In 2003, the watchdog group Public Citizen was one of the first to demand that Yaz not is
Read MoreDilantin Linked to Birth Defects Such as Cleft Palate and Cleft Lip
This is Michael Brady Lynch, lead trial attorney at The Michael Brady Lynch Firm. Dilantin is a popular anti-epilepsy drug that is also widely used off-label for mood disorders and other conditions such as nerve pain, irregular heart rhythm, and migraines. There is growing scientific evidence that use of Dilantin is associated with birth defects
Read MoreConsumer Alert! Propecia and Sexual Dysfunction
Propecia is a “vanity drug” used to treat male pattern baldness. At the 360 Advocacy Conference at which I lectured in Chicago back in April of this year, I presented to my attorney colleagues the growing scientific evidence of Propecia’s association with sexual dysfunction. The bad news is that mounting evidence supports the conclusion that
Read More